BACKGROUND: Constant improvement of HIV tests often results in withdrawal of poorer quality tests by the manufacturing companies. It is thus often necessary to evaluate new HIV testing kits and modify the existing testing strategies. OBJECTIVES: To evaluate an alternative HIV antibody testing strategy which involves consecutive testing of sera by two enzyme-linked immunosorbent assays (ELISA), which both are recombinant antigen-based but utilise different test principles, followed by re-testing of sera giving discordant results. STUDY DESIGN: Sera (n = 1558) from a cross-sectional study of the HIV-1 seroprevalence in the Kagera region of Tanzania were tested using two ELISAs in parallel: Enzygnost anti-HIV-1/2 plus and Wellcozyme HIV-1 recombinant. Western blot analysis was done on all concordantly reactive and repeatedly discordant reactive samples as well as on 10% of concordantly ELISA negative sera. RESULTS: Two hundred and four sera (13.1%) were confirmed HIV-1-antibody positive. Both ELISAs had a sensitivity of 100%. The specificities of the ELISAs at initial and repeated testing were 99.8 and 99.9%, respectively, for Enzygnost and 97.7 and 99.5%, respectively, for Wellcozyme. None of the sera was concordantly false positive in both ELISAs. The mean ratio of the optical density of a sample to the cut off value of the test run (OD/CO ratio) was lower for samples giving false positive reactions than for confirmed HIV-1-antibody-positive samples. It is therefore important to interpret with caution HIV antibody ELISA test results on samples giving low OD/CO ratios. None of 10% of randomly selected concordantly ELISA negative sera gave a positive Western blot reaction. CONCLUSIONS: This field evaluation of an HIV antibody testing strategy involving the use of a recombinant antigen-based sandwich ELISA (Enzygnost) followed by a recombinant antigen-based competitive ELISA (Wellcozyme) showed that it had a sensitivity and specificity of 100%.
BACKGROUND: Constant improvement of HIV tests often results in withdrawal of poorer quality tests by the manufacturing companies. It is thus often necessary to evaluate new HIV testing kits and modify the existing testing strategies. OBJECTIVES: To evaluate an alternative HIV antibody testing strategy which involves consecutive testing of sera by two enzyme-linked immunosorbent assays (ELISA), which both are recombinant antigen-based but utilise different test principles, followed by re-testing of sera giving discordant results. STUDY DESIGN: Sera (n = 1558) from a cross-sectional study of the HIV-1 seroprevalence in the Kagera region of Tanzania were tested using two ELISAs in parallel: Enzygnost anti-HIV-1/2 plus and Wellcozyme HIV-1 recombinant. Western blot analysis was done on all concordantly reactive and repeatedly discordant reactive samples as well as on 10% of concordantly ELISA negative sera. RESULTS: Two hundred and four sera (13.1%) were confirmed HIV-1-antibody positive. Both ELISAs had a sensitivity of 100%. The specificities of the ELISAs at initial and repeated testing were 99.8 and 99.9%, respectively, for Enzygnost and 97.7 and 99.5%, respectively, for Wellcozyme. None of the sera was concordantly false positive in both ELISAs. The mean ratio of the optical density of a sample to the cut off value of the test run (OD/CO ratio) was lower for samples giving false positive reactions than for confirmed HIV-1-antibody-positive samples. It is therefore important to interpret with caution HIV antibody ELISA test results on samples giving low OD/CO ratios. None of 10% of randomly selected concordantly ELISA negative sera gave a positive Western blot reaction. CONCLUSIONS: This field evaluation of an HIV antibody testing strategy involving the use of a recombinant antigen-based sandwich ELISA (Enzygnost) followed by a recombinant antigen-based competitive ELISA (Wellcozyme) showed that it had a sensitivity and specificity of 100%.
Authors: Darrell E Singer; Noah Kiwanuka; David Serwadda; Fred Nalugoda; Linda Hird; Jamie Bulken-Hoover; Godfrey Kigozi; Jennifer A Malia; Eva K Calero; Warren Sateren; Merlin L Robb; Fred Wabwire-Mangen; Maria Wawer; Ronald H Gray; Nelson Sewankambo; Deborah L Birx; Nelson L Michael Journal: J Clin Microbiol Date: 2005-10 Impact factor: 5.948
Authors: Freeman T Changamire; Ramadhani S Mwiru; Karen E Peterson; Gernard I Msamanga; Donna Spiegelman; Paul Petraro; Willy Urassa; Wafaie W Fawzi Journal: Matern Child Nutr Date: 2012-12-17 Impact factor: 3.092
Authors: Derryck B Klarkowski; Joseph M Wazome; Kamalini M Lokuge; Leslie Shanks; Clair F Mills; Daniel P O'Brien Journal: PLoS One Date: 2009-02-06 Impact factor: 3.240